Harrow (HROW) Short term Debt (2011 - 2024)

Harrow (HROW) posted Short term Debt of $37.0 million for Q3 2024, up 2838.84% on a QoQ basis from $1.3 million in Q4 2020.

Analysis

Harrow (HROW) Short term Debt (2011 - 2024) Analysis & Trends

Harrow has reported Short term Debt for 8 years, with the latest figure at $37.0 million in Q3 2024.

On a quarterly basis, Short term Debt changed N/A year-over-year to $37.0 million in Q3 2024; TTM through Sep 2024 was $37.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $1.3 million, changed N/A from the prior year.
Short term Debt was $37.0 million for Q3 2024 at Harrow, up from $1.3 million in the prior quarter.
The five-year high for Short term Debt was $37.0 million in Q3 2024, with the low at $827000.0 in Q2 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	646.71 Bn	625.95 Bn	17.26 Bn
2	AbbVie	442.22 Bn	435.65 Bn	12.70 Bn
3	Merck	366.92 Bn	359.78 Bn	12.21 Bn
4	Novartis Ag	266.90 Bn	259.21 Bn	11.24 Bn
5	Pfizer	159.20 Bn	147.50 Bn	10.94 Bn
6	Sanofi	52.44 Bn	45.06 Bn	10.79 Bn
7	Revolution Medicines	44.11 Bn	44.11 Bn	-
8	Incyte	25.38 Bn	20.85 Bn	1.57 Bn
9	United Therapeutics	21.50 Bn	18.84 Bn	683.80 Mn
10	Harrow	1.41 Bn	1.32 Bn	50.36 Mn

Historic Data

Download Data